Metallothionein overexpression in human brain tumours

Hans Maier, Chris Jones, Bharat Jasani, Dietmar Öfner, Bettina Zelger, Kurt Werner Schmid, Herbert Budka

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal tumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other tumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7%) showed MT expression of more than 25% of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain tumours and might be involved in their poor response to antineoplastic drugs.

Original languageEnglish
Pages (from-to)599-604
Number of pages6
JournalActa Neuropathologica
Issue number6
Publication statusPublished - Dec 12 1997


  • Gliomas
  • Immunohistochemistry
  • Meningiomas
  • Metallothioneins

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Metallothionein overexpression in human brain tumours'. Together they form a unique fingerprint.

Cite this